Accueil   Diary - News   All news Turenne Santé acquires ABL Lyon from Institut Mérieux, creating a new entity named Active Biomarkers.

Turenne Santé acquires ABL Lyon from Institut Mérieux, creating a new entity named Active Biomarkers.

 

 

ABL Lyon, a subsidiary of Institut Mérieux and a benchmark laboratory in biomarker analysis, is acquired by Turenne Santé via its private equity fund Capital Santé 2. Alongside its general manager, Marc Essodaigui, and the management team, Turenne Santé is positioning itself as majority shareholder in order to provide the company with significant resources to finance an ambitious development plan. ABL Lyon has been renamed Active Biomarkers.


Founded in 2011, ABL Lyon, now renamed Active Biomarkers, is an integrated bioanalytical laboratory with biomarker and cell-based assay testing capabilities. The company supports multiple biopharmaceutical companies in their clinical research programmes (Phases I to IV).


Positioned in a dynamic market and renowned for the quality of its services and the expertise of its team, the company has been managed by Marc Essodaigui since 2016 and has significantly increased revenue by specialising in well-targeted therapeutic fields such as oncology, infectious diseases, inflammatory pathologies and neurodegenerative diseases.

 

Read the press release